Everett Cunningham net worth and biography

Everett Cunningham Biography and Net Worth

Insider of Exact Sciences

Everett Cunningham joined as the Chief Commercial Officer in 2021. Mr. Cunningham brings over 25 years of progressive responsibility in pharmaceuticals and medical services and a commitment to leadership excellence. Prior to joining Exact Sciences, Mr. Cunningham served as President & CEO of GE Healthcare’s U.S. & Canada region. Before joining GE, Mr. Cunningham served as the Senior Vice President, Commercial, at Quest Diagnostics, where he was responsible for global commercial sales, marketing, and commercial operations.

Mr. Cunningham also served in numerous senior leadership roles at Pfizer, including Regional President, Established Products for Asia Pacific, Senior Director of Worldwide Learning and Development, Senior Director of Business Operations, Vice President Sales for U.S. Pharmaceuticals, and Vice President of Global Corporate Human Resources.

Mr. Cunningham earned his bachelor’s degree in economics from Northwestern University.

What is Everett Cunningham's net worth?: The estimated net worth of Everett Cunningham is at least $2.48 million as of May 1st, 2024. Mr. Cunningham owns 47,042 shares of Exact Sciences stock worth more than $2,479,113 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Cunningham may own. Learn More about Everett Cunningham's net worth.
How do I contact Everett Cunningham?: The corporate mailing address for Mr. Cunningham and other Exact Sciences executives is 5505 ENDEAVOR LANE, MADISON WI, 53719. Exact Sciences can also be reached via phone at (608) 284-5700 and via email at [email protected]. Learn More on Everett Cunningham's contact information.
Has Everett Cunningham been buying or selling shares of Exact Sciences?: Everett Cunningham has not been actively trading shares of Exact Sciences over the course of the past ninety days. Most recently, Everett Cunningham sold 136 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a transaction totalling $8,180.40. Following the completion of the sale, the insider now directly owns 47,042 shares of the company's stock, valued at $2,829,576.30. Learn More on Everett Cunningham's trading history.
Who are Exact Sciences' active insiders?: Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.
Are insiders buying or selling shares of Exact Sciences?: In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 36 times. They sold a total of 77,348 shares worth more than $4,737,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company. Learn More about insider trades at Exact Sciences.
Information on this page was last updated on 11/13/2024.

Everett Cunningham Insider Trading History at Exact Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2024	Sell	136	$60.15	$8,180.40	47,042
10/12/2023	Sell	13,007	$66.49	$864,835.43	37,909
10/12/2022	Sell	16,872	$31.37	$529,274.64	18,654

Everett Cunningham Buying and Selling Activity at Exact Sciences

Exact Sciences Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $52.70

$51.71

$54.17

50 Day Range

MA: $65.32

$49.33

$71.93

2 Week Range

Now: $52.70

$40.62

$79.62

Volume

2,141,771 shs

Average Volume

2,645,736 shs

Market Capitalization

$9.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.